EntryPoint Capital’s Viridian Therapeutics VRDN Stock Holding History

EntryPoint Capital’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-20,450	Closed	-$400K	–	976
2026 Q1	$400K	Buy	20,450 +10,076	+97%	+$299K	0.12%	343
2025 Q4	$323K	Hold	10,374	–	–	0.13%	329
2025 Q3	$224K	Sell	10,374 -2,858	-22%	-$51.5K	0.09%	502
2025 Q2	$185K	Sell	13,232 -510	-4%	-$6.92K	0.09%	501
2025 Q1	$185K	Buy	+13,742	New	+$234K	0.08%	555
2024 Q3	–	Sell	-5,569	Closed	-$72.5K	–	1389
2024 Q2	$72.5K	Buy	+5,569	New	+$77.1K	0.03%	956

Other funds holding VRDN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

EntryPoint Capital's VRDN Position: Q2 2026 in Review

EntryPoint Capital sold out of Viridian Therapeutics (VRDN) in Q2 2026, closing a stake of 20,450 shares — an estimated $400K sold.

EntryPoint Capital first reported a position in VRDN in Q2 2024 and held it in 6 quarters. The position peaked at $400K in Q1 2026. 215 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

EntryPoint Capital reported no remaining Viridian Therapeutics position as of Q2 2026 after selling out during the quarter.
EntryPoint Capital sold 20,450 Viridian Therapeutics shares in Q2 2026, an estimated $400K.
EntryPoint Capital first reported a position in Viridian Therapeutics in Q2 2024 and held it in 6 quarters.
EntryPoint Capital's Viridian Therapeutics position peaked at $400K in Q1 2026.
215 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.